{
  "meta": {
    "timestamp": "2025-01-06T14:19:06.425778",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Neumora Therapeutics Inc.",
      "symbol": "NMRA",
      "analysis": {
        "historical": {
          "risk_score": 85,
          "key_risks": [
            "Clinical trial failure of lead drug candidate navacaprant (NMRA-001)",
            "High risk of pipeline setbacks due to clinical-stage biotech nature",
            "Dependence on strategic partnerships, particularly with Amgen",
            "Regulatory and competitive challenges in neuroscience market",
            "Potential financial strain from stock decline and reliance on external funding"
          ],
          "controversies": [
            "Securities fraud investigation",
            "Significant stock plunge following Phase 3 trial failure",
            "Unusual options trading activity indicating investor speculation"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Unmet need for effective treatments for major depressive disorder (MDD)",
            "Ethical responsibility to manage investor and patient expectations transparently"
          ],
          "governance_issues": [
            "Questions about corporate governance and transparency due to securities fraud investigation"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Neumora fails phase 3 depression trial, sending stock down 80%",
              "snippet": "Neumora Therapeutics' big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage readouts on Neumora's lead drug candidate has ended in failure, wiping ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538342+00:00",
              "published_date": null,
              "source_hash": "b910e74d95cbf57d3c3509378e98caa7"
            },
            {
              "url": "",
              "title": "Neumora Plunges After Major Depression Drug Fails in Study",
              "snippet": "Neumora Therapeutics Inc.'s shares plummeted the most on record after the company's experimental drug for the treatment of major depressive disorder failed to show a benefit in a final-stage ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538312+00:00",
              "published_date": null,
              "source_hash": "3b6f63a69ac74bf4ef922e33ac14b87e"
            },
            {
              "url": "",
              "title": "Neumora shares slump after depression drug fails in key trial",
              "snippet": "Neumora Therapeutics' shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and pessimistic thoughts in a key study, raising ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538332+00:00",
              "published_date": null,
              "source_hash": "e8e418b4844574c0ec893b59f75af50e"
            },
            {
              "url": "",
              "title": "Neumora stock drops on depression trial failure (NMRA:NASDAQ)",
              "snippet": "Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder didn't meet main goals. Read more here.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:41.448793+00:00",
              "published_date": null,
              "source_hash": "9f363e45942752e8e825f087f3ef3ede"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics' stock craters after trial of major ... - MSN",
              "snippet": "Neumora Therapeutics Inc.'s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals. The ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:41.448802+00:00",
              "published_date": null,
              "source_hash": "ec06681a71193bcb6e384b42b532e593"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant ...",
              "snippet": "WATERTOWN, Mass., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:41.448811+00:00",
              "published_date": null,
              "source_hash": "edc7305bf01dfac774e2a2983ebc78b0"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics' stock craters after trial of major depressive ...",
              "snippet": "Neumora Therapeutics Inc.'s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538359+00:00",
              "published_date": null,
              "source_hash": "3fa8e1a54b5054775c6095dc57c560fb"
            },
            {
              "url": "",
              "title": "Neumora's Novel Depression Drug Strikes Out in First Pivotal Trial",
              "snippet": "The downward trend set in depression in 2024 continued into the New Year as Neumora Therapeutics reported that its highly anticipated major depressive disorder candidate navacaprant failed the first of three Phase III trials.. A kappa opioid receptor (KOR) antagonist, navacaprant is designed to modulate the dopamine and reward processing pathways, which play a central role in the regulation of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:41.448831+00:00",
              "published_date": null,
              "source_hash": "e272b3383f6942a5b043270936ca4845"
            },
            {
              "url": "",
              "title": "Neumora trial failure a 'big blow' to bull case, says Stifel",
              "snippet": "After Neumora Therapeutics (NMRA) announced the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder did not demonstrate a statistically significant improvement on ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:41.448841+00:00",
              "published_date": null,
              "source_hash": "3aeda82fb51e4c6275045c040a0b9ba7"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics, Inc. (NMRA) - Stock Analysis",
              "snippet": "Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:41.448849+00:00",
              "published_date": null,
              "source_hash": "3002ac33b677ab46ea15076e19f35ba1"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA)",
              "snippet": "Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 5,936 call options on the stock. This represents an increase of 45% compared to the average volume of 4,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:52.101252+00:00",
              "published_date": "2025-01-06T15:20:00+00:00",
              "source_hash": "c1f43698b2b6992cb97da102c8667211"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA",
              "snippet": "Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:52.101305+00:00",
              "published_date": "2025-01-03T03:40:00+00:00",
              "source_hash": "d0fc3621265fd7083502ced015ff7d7c"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Inc (NMRA) Stock: Surpassing Expectations in the Market?",
              "snippet": "Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and touched a low of $2.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:52.101327+00:00",
              "published_date": "2025-01-06T14:02:00+00:00",
              "source_hash": "13a69373a7d6d6c0487492eb75337c3f"
            },
            {
              "url": "",
              "title": "RBC downgrades Neumora Therapeutics to Sector Perform after trial failure",
              "snippet": "RBC Capital downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $29, following lead",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:43.953454+00:00",
              "published_date": "2025-01-02T16:10:00+00:00",
              "source_hash": "a9159a4f230a4ccff68c971edd330304"
            },
            {
              "url": "",
              "title": "Neumora drops as depression therapy fails in late-stage trial",
              "snippet": "Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder didn't meet main goals. Read more here.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:18:43.953463+00:00",
              "published_date": "2025-01-02T11:22:00+00:00",
              "source_hash": "356f09e8dec782e775823aba5f004720"
            },
            {
              "url": "",
              "title": "Neumora shares slump after depression drug fails in key trial",
              "snippet": "Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:45.648129+00:00",
              "published_date": null,
              "source_hash": "a492b309ce1f5e71a3210c9138053d2b"
            },
            {
              "url": "",
              "title": "Neumora Stock Hits Record Low on Depression Drug Study Failure",
              "snippet": "Neumora Therapeutics, Inc. price | Neumora Therapeutics, Inc. Quote. Key Picks Among Biotech Stocks. Some better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:45.648247+00:00",
              "published_date": null,
              "source_hash": "42078aa2a460d48f081ddbddaa53f51a"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals",
              "snippet": "Neumora Therapeutics shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet its ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538350+00:00",
              "published_date": null,
              "source_hash": "acdead0d7c74283c35a946a459111036"
            },
            {
              "url": "",
              "title": "Neumora's Novel Depression Drug Strikes Out in First ... - BioSpace",
              "snippet": "Neumora is far from the only biopharma company to suffer a recent failure in MDD. Last month, Relmada Therapeutics halted two Phase III trials of its MDD candidate REL-1017 after an independent Data Monitoring Committee determined the drug was unlikely to succeed. And in October, Alto Neuroscience reported that a trial of ALTO-100 failed to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:45.648267+00:00",
              "published_date": null,
              "source_hash": "728935da2c67584f2cbac5bb49acdd59"
            },
            {
              "url": "",
              "title": "Stock in Biotech Neumora Plunges 80% as Depression Drug Fails",
              "snippet": "Continue reading this article with a Barron's subscription. SUBSCRIBE NOW. Topics. Cryptocurrencies; Data; Magazine; Markets; Stock Picks",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:45.648287+00:00",
              "published_date": null,
              "source_hash": "f83a6d87069f075d84eab13401dff623"
            },
            {
              "url": "",
              "title": "Neumora's antidepressant stumbles in first Phase 3 trial readout - STAT",
              "snippet": "A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial \u2014 the company's first late-stage readout. ... 3 key issues to watch at the FDA as Trump ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:45.648296+00:00",
              "published_date": null,
              "source_hash": "a93de680136c589d493556109dd4e4f3"
            },
            {
              "url": "",
              "title": "Neumora's early-stage schizophrenia drug study put on hold",
              "snippet": "Neumora Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on early-stage study of its experimental schizophrenia drug, sending its shares down more ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:45.648312+00:00",
              "published_date": null,
              "source_hash": "95f1d8da1d2246233eb07d71771affbd"
            },
            {
              "url": "",
              "title": "Redefining Neuroscience Drug Development - Neumora Therapeutics, Inc.",
              "snippet": "Neumora is Tackling One of the Largest Population Health Challenges Neumora's clinical-stage pipeline has potential to reach up to ~40M+ patients starting in 2026 with a robust IP runway into 2041+ 1National Institutes of Health. Our Biggest Health Challenges. Accessed December 2023. Note: Figure not intended as launch guidance or order.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538379+00:00",
              "published_date": null,
              "source_hash": "52eb135caff7321c501ab28c55024cb4"
            },
            {
              "url": "",
              "title": "Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)",
              "snippet": "Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA - Research Report) and",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:52.101336+00:00",
              "published_date": "2025-01-06T00:10:00+00:00",
              "source_hash": "be1181335677161ad928d89db3626b1e"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Inc NMRA",
              "snippet": "We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:18:48.103755+00:00",
              "published_date": "2025-01-03T13:00:00+00:00",
              "source_hash": "565e1eb9dccdc02105d1c035fa5a47c8"
            },
            {
              "url": "",
              "title": "Neumora Stock Hits Record Low on Depression Drug Study Failure - MSN",
              "snippet": "Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD).",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538176+00:00",
              "published_date": null,
              "source_hash": "d41559590b03199c5b7acd04dab3c4bd"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Reports Disappointing Results from KOASTAL-1 Study ...",
              "snippet": "Neumora Therapeutics, Inc. (NASDAQ: NMRA) recently disclosed the outcome of its Phase 3 KOASTAL-1 study for navacaprant in the treatment of major depressive disorder (MDD). The company revealed that the study did not display a statistically significant enhancement in the primary endpoint of lowering depressive symptoms compared to the placebo. In a press release issued [\u2026]",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538290+00:00",
              "published_date": null,
              "source_hash": "bf97cc99be54ea3157cdf7ac2274525c"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics Reports Disappointing Results ... - ETF Daily News",
              "snippet": "Neumora Therapeutics, Inc. (NASDAQ: NMRA) recently disclosed the outcome of its Phase 3 KOASTAL-1 study for navacaprant in the treatment of major depressive disorder (MDD). The company revealed ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538323+00:00",
              "published_date": null,
              "source_hash": "468183b2f132372cfa5373de73e54a68"
            },
            {
              "url": "",
              "title": "Neumora",
              "snippet": "Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:49.538367+00:00",
              "published_date": null,
              "source_hash": "bc1d592bc1a9e038ee78a29b7b5c383b"
            },
            {
              "url": "",
              "title": "Neumora Therapeutics price target lowered to $7 from $22 at BofA",
              "snippet": "BofA analyst Geoff Meacham lowered the firm's price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Neumora Therapeutics Inc. Neumora Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:18:52.101317+00:00",
              "published_date": "2025-01-06T00:00:00+00:00",
              "source_hash": "52a1131835e46ddf173ada3565ed7c6c"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Neumora Therapeutics Inc. clinical trial failures",
              "rationale": "Investigate potential risks associated with the failure of drug candidates in clinical trials, which could impact valuation and funding",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Neumora Therapeutics Inc. regulatory challenges FDA",
              "rationale": "Examine potential delays or setbacks in gaining regulatory approval for therapies targeting brain diseases",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Neumora Therapeutics Inc. patient safety concerns",
              "rationale": "Assess any ethical or social concerns related to patient safety in clinical trials for neurological and psychiatric disorders",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:19:06.425789",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}